AbbVie not to seek accelerated approval for Rova-T after weak phase 2 SCLC trial data
The company said that it had consulted with the US Food and Drug Administration (FDA) and took the decision not to pursue the accelerated approval for the lung
The US Food and Drug Administration (FDA) has granted clearance for RiboX Therapeutics’ investigational new drug (IND) application to commence a Phase I/IIa clinical trial of RXRG001, circular RNA therapy.
The partnership will focus on developing three proteins, including tau, TDP-43 and an undisclosed target, implicated in the pathogenesis of various neurodegenerative diseases. Celgene will be provided with
Belimumab and rituximab have different but potentially complementary mechanisms of action. This study will assess whether co-administration enhances the treatment effect of belimumab and provides sustained disease control,